Proteologix’s antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma.
Trending
- NITDA, CAC strengthen cybersecurity measures
- Naira ends week slightly lower
- YABATECH boosts skills in stop-motion animation
- Abia gov mourns US-based doctor’s death
- NGX urges collaboration for digital asset growth
- New science labs onated to Oshodi school
- Nigerian freelancers face rising financial pressure
- Airtime borrowing myths debunked by FCCPC
